Fig. 6
From: The molecular basis of the anticancer effect of statins
Lovastatin validation of the Synthetic Lethality hypothesis. Half-maximal inhibitory concentration (IC50) is determined for different cancer cell lines, after 72 h of treatment with Lovastatin. (a) The MDA-MB-231 cell line, harboring a mutated KRAS gene that forms an SL pair with HMGCR, demonstrated an IC50 value of 9.5 nM, R2 = 0.8. (b) The HCC1937 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 8.7 µM, R2 = 0.82. (c) The OVPA8 cell line, harboring a mutated BRCA1 gene that forms an SL pair with HDAC2, demonstrated an IC50 value of 522 nM, R2 = 0.78. (d) The HeLa cell line, devoid of mutations that form SL pairs with the target genes of Lovastain, remains unaffected across all tested Lovastatin concentrations.
